You are not logged in.

Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics

Davies, Katherine M, Mercer, Julian FB, Chen, Nicholas and Double, Kay L 2016, Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics, Clinical science, vol. 130, no. 8, pp. 565-574, doi: 10.1042/CS20150153.

Attached Files
Name Description MIMEType Size Downloads

Title Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics
Author(s) Davies, Katherine M
Mercer, Julian FB
Chen, Nicholas
Double, Kay L
Journal name Clinical science
Volume number 130
Issue number 8
Start page 565
End page 574
Total pages 10
Publisher Portland Press
Place of publication London, Eng.
Publication date 2016
ISSN 0143-5221
1470-8736
Keyword(s) Parkinson's disease
brain
copper
homoeostasis
neurodegeneration
therapy
Animals
Antiparkinson Agents
Homeostasis
Humans
Oxidative Stress
Parkinson Disease
alpha-Synuclein
Summary Copper is a biometal essential for normal brain development and function, thus copper deficiency or excess results in central nervous system disease. Well-characterized disorders of disrupted copper homoeostasis with neuronal degeneration include Menkes disease and Wilson's disease but a large body of evidence also implicates disrupted copper pathways in other neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease and prion diseases. In this short review we critically evaluate the data regarding changes in systemic and brain copper levels in Parkinson's disease, where alterations in brain copper are associated with regional neuronal cell death and disease pathology. We review copper regulating mechanisms in the human brain and the effects of dysfunction within these systems. We then examine the evidence for a role for copper in pathogenic processes in Parkinson's disease and consider reports of diverse copper-modulating strategies in in vitro and in vivo models of this disorder. Copper-modulating therapies are currently advancing through clinical trials for Alzheimer's and Huntington's disease and may also hold promise as disease modifying agents in Parkinson's disease.
Language eng
DOI 10.1042/CS20150153
Field of Research 119999 Medical and Health Sciences not elsewhere classified
11 Medical And Health Sciences
Socio Economic Objective 970106 Expanding Knowledge in the Biological Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30090168

Document type: Journal Article
Collection: Centre for Cellular and Molecular Biology
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in TR Web of Science
Scopus Citation Count Cited 10 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 24 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Thu, 06 Apr 2017, 11:08:48 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.